Medical

chylomicronemia syndrome

Also found in: Dictionary, Encyclopedia.

chylomicronemia syndrome

Hyperchylomicronemia A condition characterized by marked chylomicronemia with plasma TG levels > 225 mmol/L–US: 2000 mg/dL Clinical Abdominal and chest pain, pancreatitis, memory defects, carpal tunnel-like paresthesiae, hepatosplenomegaly, chronic eruptive xanthomata, and insulin-resistant DM, possibly related to marked hypertriglyceridemia; Sx are exacerbated by alcohol, β blockers, diuretics, estrogens, glucocorticoids
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
Mentioned in
References in periodicals archive
Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl.
This was also the first time I heard the term familial chylomicronemia syndrome (FCS), which is a term used to describe LPLD and the other mutations that can cause this syndrome.
Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver C, Baudet A, Sly W, Valle D, eds.
The product is intended for the treatment of patients with Familial Chylomicronemia Syndrome. FCS is a rare genetic disease characterized by extremely high triglyceride levels and risk of pancreatitis.
Akcea Therapeutics announced the publication of results from the first-ever study demonstrating the benefits of patient-to-patient connectivity in the management of familial chylomicronemia syndrome. FCS is a rare, potentially life-threatening disease with multiple severe, daily and chronic manifestations that affect one's ability to work and engage in activities of everyday living.
M2 EQUITYBITES-July 7, 2015-Akcea Therapeutics wins US FDA's orphan drug designation for Volanesorsen for treating Familial Chylomicronemia Syndrome
Akcea Therapeutics (AKCA), up 11% after an FDA advisory committee voted 12-8 to support approval of volanesorsen for the treatment of people with familial chylomicronemia syndrome. DOWN AFTER EARNINGS: Nvidia (NVDA), down 2.5%...
The most advanced drug in its pipeline, volanesorsen, has successfully completed a Phase 3 clinical program for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy, or FPL.
Drug company Isis Pharmaceuticals (NasdaqGS:ISIS) announced on Thursday that it has initiated a Phase 3 study evaluating ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS), a rare orphan disease that is characterised by extremely high triglyceride levels.
Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.